Additional AXL inhibitors include PF-07265807 (ARRY-067), a small-molecule inhibitor of both AXL and MER kinases, that is currently in phase 1 development in combination with ICI and a VEGF TKI for the treatment of advanced ccRCC (NCT04458259). This evidence concerns the gene AXL and nonpapillary renal cell carcinoma.